Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Phase 2 Recruiting 40 enrolled The First Affiliated Hospital of Xiamen University

Non-randomizedParallel-groupOpen-labelTreatment

To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	70 mg/m2	Other
Subject	Docetaxel	Small molecule	70 mg/m2	Other
Subject	Goserelin	Other / unclassified	3.6 mg	Intramuscular
Subject	Pamiparib	Small molecule	60 mg	Oral
Subject	Rezvilutamide	Small molecule	240 mg	Oral
Subject	Tislelizumab	Monoclonal antibody	200 mg	Other